Clinical Trials Logo
  1. Home
  2. Pandemic Influenza
  3. NCT00519389

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

Pandemic Influenza Clinical Trial

Official title:
A Phase I/IIa Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an H5N1 Virus-Like Particle (VLP) Influenza Vaccine (Recombinant)

Clinical Trial Summary

This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, reactogenicity, and immunogenicity of 3 potencies (dosages) of H5N1 VLP vaccine or placebo in healthy adults 18 to 40 years of age.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00519389
Study type Interventional
Source Novavax
Contact
Status Completed
Phase Phase 1/Phase 2
Start date July 2007
Completion date November 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT00976469 - A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents Phase 1/Phase 2
Completed NCT00971542 - Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age Phase 3
Completed NCT00535665 - Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine Phase 2
Completed NCT00950456 - Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine N/A
Completed NCT00908687 - A/H5N1/LT Dose Ranging Study Phase 2
Completed NCT00783926 - Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant) Phase 1
Recruiting NCT06046092 - H7HLAII DNA Influenza Vaccine Phase 1
Completed NCT01640691 - Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults Phase 1/Phase 2
Completed NCT01053143 - Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India Phase 3
Completed NCT00660257 - Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine Phase 1
Completed NCT00457509 - Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults Phase 1
Completed NCT00971100 - Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age Phase 3
Completed NCT00959465 - A/H1N1 Immunogenicity and Safety in Adults Phase 1/Phase 2
Completed NCT00970177 - Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age Phase 3
Completed NCT00971906 - Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age Phase 3
Completed NCT00532792 - A/H5N1 Dose Ranging Study With Adjuvant Patch Phase 1
Withdrawn NCT00640874 - A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza N/A
Withdrawn NCT00640211 - A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B N/A
Withdrawn NCT00640302 - A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza N/A